No Data
Beijing Bohui Innovation Biotechnology Group (300318.SZ): received government subsidies of 2.9 million yuan.
Gelonghui, on April 3, announced that Beijing Bohui Innovation Biotechnology Group (300318.SZ) received government subsidy funds of 2.9 million yuan on April 2, 2025, accounting for 11.63% of the net income attributable to shareholders of the listed company for the fiscal year 2023.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): Clinical trial approval for the trivalent influenza virus subunit vaccine.
beijing bohui innovation biotechnology group (300318.SZ) announced that the company's controlling subsidiary, bohui biopharmaceutical co., ltd. (referred to as "...
Beijing Bohui Innovation Biotechnology Group's subsidiary plasma station has obtained a single plasma collection license.
Beijing Bohui Innovation Biotechnology Group (300318.SZ) announced that recently, the company's holding subsidiary Guangdong Weilon Biopharmaceutical Co., Ltd...
Bohui Innovation: 2024 Annual Performance Forecast
Beijing Bohui Innovation Biotechnology Group (300318.SZ): Expected net profit for the year 2024 is between 8.5 million yuan and 12.7 million yuan.
On January 20, Gelonghui reported that Beijing Bohui Innovation Biotechnology Group (300318.SZ) announced its performance forecast for 2024, projecting a net income attributable to shareholders of the listed company to be between 8.5 million yuan and 12.7 million yuan, compared to a loss of 24.9294 million yuan in the same period last year; the net income after deducting non-recurring gains and losses is expected to be between 10.8 million yuan and 15 million yuan, against a loss of 27.6577 million yuan in the same period last year. During the reporting period, the company’s revenue declined year-on-year, and operating profit decreased, but the company strictly controlled various cost and expense expenditures, therefore the net income is still expected to show a profit status.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The company's Yunnan blood product factory has been completed and is currently pushing forward various process works.
On December 23, Glonghui reported that Beijing Bohui Innovation Biotechnology Group (300318.SZ) stated on the investor interaction platform that the Yunnan blood product factory has been completed. The company is currently advancing the product process validation, changes in the pharmaceutical marketing authorization holder, production site and pharmaceutical research, and change approvals in accordance with the "Measures for the Administration of Changes After Drug Marketing" and other relevant normative documents and technical guidance principles. The company is currently unable to accurately predict the completion time for all processes and the specific start time for production.